XSHE002038
Market cap1.02bUSD
Jan 22, Last price
7.27CNY
1D
0.55%
1Q
-4.72%
Jan 2017
-59.18%
Name
Beijing SL Pharmaceutical Co Ltd
Chart & Performance
Profile
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,018,359 -3.03% | 1,050,165 -13.55% | |||||||
Cost of revenue | 641,496 | 768,904 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 376,862 | 281,261 | |||||||
NOPBT Margin | 37.01% | 26.78% | |||||||
Operating Taxes | 49,937 | 31,010 | |||||||
Tax Rate | 13.25% | 11.03% | |||||||
NOPAT | 326,925 | 250,252 | |||||||
Net income | 416,692 77.77% | 234,404 -44.97% | |||||||
Dividends | (102,735) | (102,735) | |||||||
Dividend yield | 0.99% | 1.22% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | (27,873) | ||||||||
Long-term debt | |||||||||
Deferred revenue | 47,041 | 51,379 | |||||||
Other long-term liabilities | |||||||||
Net debt | (3,665,509) | (2,062,966) | |||||||
Cash flow | |||||||||
Cash from operating activities | 460,197 | 389,821 | |||||||
CAPEX | (218,360) | ||||||||
Cash from investing activities | (378,027) | ||||||||
Cash from financing activities | (102,735) | (102,735) | |||||||
FCF | 996,236 | 368,752 | |||||||
Balance | |||||||||
Cash | 2,078,251 | 739,944 | |||||||
Long term investments | 1,587,258 | 1,295,149 | |||||||
Excess cash | 3,614,591 | 1,982,585 | |||||||
Stockholders' equity | 5,809,607 | 5,478,808 | |||||||
Invested Capital | 2,349,766 | 3,511,177 | |||||||
ROIC | 11.16% | 7.46% | |||||||
ROCE | 6.27% | 5.07% | |||||||
EV | |||||||||
Common stock shares outstanding | 1,016,322 | 1,027,350 | |||||||
Price | 10.19 23.97% | 8.22 -23.96% | |||||||
Market cap | 10,356,319 22.64% | 8,444,817 -23.96% | |||||||
EV | 6,700,232 | 6,393,007 | |||||||
EBITDA | 522,537 | 395,140 | |||||||
EV/EBITDA | 12.82 | 16.18 | |||||||
Interest | 66 | 103 | |||||||
Interest/NOPBT | 0.02% | 0.04% |